Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Waled Bahaj

Internal Medicine Indianapolis, IN Medical Doctor

NPI 1316300601 CMS profile 2551404

8111 S Emerson Ave Ste 105, Indianapolis, IN 46237

Open in the dashboard

General payments

$8,917

373 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Waled Bahaj of Indianapolis, IN is reported in the CMS Open Payments database as having received $8,917 across 373 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,954 93
2024 General $3,242 138
2023 General $2,135 96
2022 General $1,546 44
2021 General $26 1
2019 General $14 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Waled Bahaj
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Waled Bahaj were reported at $1,954. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Waled Bahaj Internal Medicine median Middle half National median
2019 $14 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $26 $135 $37–$521 $132
2022 $1,546 $141 $42–$496 $149
2023 $2,135 $149 $45–$519 $160
2024 $3,242 $154 $47–$537 $164
2025 $1,954 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Daiichi Sankyo Inc. $819 34 payments
  2. Novartis Pharmaceuticals Corporation $741 38 payments
  3. Incyte Corporation $667 29 payments
  4. Genzyme Corporation $502 10 payments
  5. E.R. Squibb & Sons, L.L.C. $424 28 payments
  6. Pfizer Inc. $387 19 payments
  7. Amgen Inc. $349 10 payments
  8. Janssen Biotech, Inc. $338 16 payments
  9. Seattle Genetics, Inc. $338 8 payments
  10. Adaptive Biotechnologies Corporation $311 7 payments
  11. Other $4,042 174 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,089 363 payments
  2. Education $828 10 payments
Products named General payments · program years 2019–2025
  1. ENHERTU $736 29 payments
  2. JAKAFI $391 23 payments
  3. CABLIVI $334 7 payments
  4. IMBRUVICA $330 12 payments
  5. Empaveli $289 6 payments
  6. OPDIVO $269 17 payments
  7. Tavalisse $240 12 payments
  8. clonoSEQ $237 4 payments
  9. ULTOMIRIS $223 6 payments
  10. Rezlidhia $218 11 payments
  11. Other $5,622 272 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

18

Median for Internal Medicine: 777

Drug cost

$13,729

Median for Internal Medicine: $73,373

Branded share of claims

100%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 18 $13,729

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$13,027

Medicare's payments for the services billed

Medicare patients

71

Average age 76

Services billed

150

40 women, 31 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 56%
Arthritis 55%
Ischemic heart disease 48%
Chronic kidney disease 48%
Diabetes 46%
Atrial fibrillation 42%
COPD 42%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 46 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
  • Daiichi Sankyo Inc. $493
  • AstraZeneca Pharmaceuticals LP $18
$510 — —
Fabhalta
  • Novartis Pharmaceuticals Corporation $133
$133 — —
JAKAFI
  • Incyte Corporation $123
$123 — —
OPDIVO
  • E.R. Squibb & Sons, L.L.C. $122
$122 — —
CARVYKTI
  • Janssen Biotech, Inc. $105
$105 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 46 with Patron

Records

373 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record